Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02321995
Other study ID # Pro00057177
Secondary ID
Status Completed
Phase N/A
First received December 17, 2014
Last updated June 28, 2017
Start date June 2016
Est. completion date October 2016

Study information

Verified date June 2017
Source Zenalux Biomedical, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to evaluate the Zenalux IM1, an optical spectroscopy device with a pressure sensor. The pressure sensor is intended to overcome the inconsistencies attributable to variations in use of the device. This study will involve using the device on healthy volunteers. Three tissue parameters will be used to analyze the pressure effects in two ways: within- and across-subject variability. Measurements will be taken under the tongue and on the inside of the cheek. The device is noninvasive and is approved for preclinical use.


Description:

PURPOSE OF THE STUDY:

1. There exist significant systematic and random errors in the in vivo spectroscopic measurement of tissue hemoglobin concentrations, blood oxygenation, and scattering coefficient due to uncontrolled probe-to-tissue interface and the lack of a real-time calibration.

2. It is possible to design and engineer a fiber optic sensor to perform accurate and reproducible diffuse reflectance spectroscopy (DRS) for noninvasive quantification of tissue physiology and morphology in vivo. Features such as probe pressure control and instrument self-calibration will improve signal-to-noise ratios by removing user bias from optical measurements.

STUDY OBJECTIVES

1) Evaluation of the pressure sensor in healthy volunteers to determine the minimum contact pressure required for spectroscopic measurements

DESIGN AND PROCEDURES:

Evaluation of the pressure sensor in a volunteer study (n=10)

Informed consent will be obtained from all volunteers. In order to assess the pressure sensor, all research procedures will be repeated twice (once with the aid of the stepper motor and once without the aid of the stepper motor.) For the first five subjects, measurements will be made with the stepper motor first followed by measurements without the stepper motor. The remaining five-subjects will receive the measurements in the reverse order (no stepper motor following by stepper motor). Before the optical measurements, all subjects will be asked to rinse their mouth with a 0.9% saline solution in order to minimize the influence of consumed food. The instrument is high-level disinfected prior to each use in cidex or sterilized by ethylene oxide per standard clinical procedure. Furthermore, it is not anticipated that this device will pose a significant risk to vulnerable populations. The probe will be covered with an optically clear protective sterile sheath and placed in contact with the soft tissue. Reflectance measurements will be taken from each volunteer at up to 5 pressure levels (25, 50, 75, 100, 150 mmHg). At each pressure level 10 spectra will be acquired sequentially. The first measurement will start immediately after the desired probe pressure is reached. This will generate a total of 100 sample and calibration spectra pairs from each subject. This will be repeated on other sites including the tongue, cheek and gums. The sample spectrum will be calibrated using the calibration spectrum collected concurrently. Three tissue parameters will be used to analyze the pressure effects which is described here with [THb] as an example: First, the mean [THb] and its standard deviation will be calculated from the 10 repeat measurements at each pressure for each subject for measurements with and without the stepper motor and plotted against the probe pressure (refer to as THb-P curve). Second, at each pressure level, the [THb] will be plotted against time for each subject and the curve will indicate the temporal response of the tissue under that probe pressure. A series of paired t-tests will be used to identify the contact pressure at which minimal [THb] variance occurs over time (when stepper motor is used). Next, the variance at that contact pressure will be compared to the case without the stepper motor to demonstrate a significant reduction in pressure variance.

The investigators do not anticipate any risks to participants, however, there are a few potential minimal risks such as loss of confidentiality; slight risk of infection; discomfort at the pressure sites; and jaw discomfort as a result of the mouth being opened for several minutes.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date October 2016
Est. primary completion date October 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Healthy volunteer with no presentation of disease (such as no complaints or self-reported oral symptoms or lesions; no cold or flu like symptoms) that would affect the reflective measurements in the oral cavity

- Age 18 or older

- Subjects of all ethnic and gender groups will be included

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Subjects considered in "vulnerable" populations such as children under the age of 18

- Complaint of oral symptoms or lesions

- Current cold or flu like symptoms (self-reported)

- Pregnancy (self-reported by menstrual history)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Duke University Medical Center Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Zenalux Biomedical, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary minimum contact pressure required for spectroscopic measurements at the time the optical measurements are collected
See also
  Status Clinical Trial Phase
Completed NCT06326723 - Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects Phase 1
Recruiting NCT00001367 - Diagnosis and History Study of Patients With Different Neurological Conditions
Completed NCT02699710 - Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects Phase 1
Completed NCT02231892 - Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study N/A
Not yet recruiting NCT06441916 - Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions Phase 1
Completed NCT03771586 - A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects Phase 1
Not yet recruiting NCT06337422 - Bioequivalence Study of Generic Celecoxib 200 mg Capsules Phase 1
Completed NCT03302182 - Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects Phase 1
Completed NCT05049343 - Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants Phase 1
Recruiting NCT01629108 - Normal Values in Hearing and Balance Testing
Completed NCT02947854 - Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant Phase 1
Completed NCT02534870 - Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects Phase 1
Completed NCT02224053 - Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers Phase 1
Completed NCT01711762 - A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers Phase 1
Completed NCT01684891 - A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers Phase 1
Completed NCT01697436 - A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets Phase 1
Completed NCT01676584 - A Study of Single Dose RO6811135 in Healthy Volunteers Phase 1
Completed NCT01414881 - Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects Phase 1
Completed NCT02547259 - Influence of Emotion in a Test Run Forgetfulness N/A
Completed NCT01461967 - A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers Phase 1